Washington Capital Management Inc. Increases Holdings in Bruker Corporation $BRKR

Washington Capital Management Inc. boosted its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 2.3% in the 2nd quarter, Holdings Channel reports. The fund owned 22,245 shares of the medical research company’s stock after buying an additional 490 shares during the period. Washington Capital Management Inc.’s holdings in Bruker were worth $916,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BRKR. Signaturefd LLC increased its position in shares of Bruker by 58.6% during the second quarter. Signaturefd LLC now owns 1,662 shares of the medical research company’s stock worth $68,000 after purchasing an additional 614 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in Bruker by 60.8% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 55,672 shares of the medical research company’s stock worth $2,294,000 after purchasing an additional 21,043 shares during the period. Forte Capital LLC ADV raised its position in shares of Bruker by 10.2% during the 2nd quarter. Forte Capital LLC ADV now owns 9,615 shares of the medical research company’s stock worth $396,000 after acquiring an additional 890 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Bruker by 139.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,225 shares of the medical research company’s stock worth $133,000 after acquiring an additional 1,877 shares in the last quarter. Finally, Kaufman Rossin Wealth LLC grew its stake in Bruker by 14.7% during the 2nd quarter. Kaufman Rossin Wealth LLC now owns 5,654 shares of the medical research company’s stock worth $233,000 after buying an additional 725 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 27.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BRKR has been the subject of several recent analyst reports. Citigroup reduced their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Barclays cut their price target on Bruker from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Monday, August 4th. Bank of America cut their price target on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the company a “buy” rating in a research report on Monday, August 4th. Finally, Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $51.30.

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $31.04 on Monday. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $72.94. The stock has a fifty day moving average price of $34.04 and a two-hundred day moving average price of $37.83. The firm has a market cap of $4.71 billion, a P/E ratio of 59.69, a PEG ratio of 4.32 and a beta of 1.22. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million during the quarter, compared to analysts’ expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Research analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker’s dividend payout ratio (DPR) is currently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.